The cell line development market is growing at a CAGR of approximately 8-10% due to the increasing adoption of cell-based ...

MK-1084, Merck’s investigational KRAS G12C inhibitor, showed a manageable safety profile along with antitumor activity in the ...

Immatics’ cell therapy has been linked to a 56% objective response rate (ORR) among 32 heavily pretreated patients with ...

This country research report on Vietnam Primary Cell Culture Market offers comprehensive insights into the market landscape, customer intelligence, and competitive strategies in the Vietnam market.

SaveHealth provides an in-depth look at cholesterol-fighting atorvastatin, its mechanism of action, clinical significance, ...

Merck KGaA has shown off data that fueled its $85 million bet on a late-phase treatment for a rare, locally aggressive tumor.

During a live event, Konstantinos Sdrimas, MD, asked participants what community oncologists should consider when referring ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

Phase III progression-free survival data were positive for first-line Braftovi in first-line combination therapy for mCRC.